|Bid||0.0000 x 1800|
|Ask||0.0000 x 1300|
|Day's Range||0.3600 - 0.3600|
|52 Week Range||0.2500 - 4.0000|
|Beta (5Y Monthly)||0.52|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.25|
Subscribe to Yahoo Finance Plus to view Fair Value for EMMA
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update.
By Brad Sorensen, CFA OTC:EMMA READ THE FULL EMMA RESEARCH REPORT Emmaus Life Sciences, Inc. (OTC:EMMA) is expanding the reach of Endari, its treatment for sickle cell disease, while also pursuing other treatments to add to its portfolio. The company had shown the ability of bringing a treatment to commercialization and we believe the market is not fully recognizing the potential Emmaus has to
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the recent engagement of Acorn Management Partners, LLC to provided professional relations and consulting services to build investor awareness of Emmaus.